Tradestie Institutional Equity Comparison Engine

GNPX vs REGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, GNPX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus REGN at 14.8x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, GNPX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
GNPX N/M vs REGN 14.8x Fwd P/E
Growth & Margin Winner REGN
Op Margin 0.0% vs 30.4% ยท YoY +0.0% vs +36.3%
Momentum & Technical Winner REGN
1Y -56.6% vs +31.0% ยท 52W Pos 11% vs 82%
Options & Structure Winner REGN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (6th %ile IV)
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
1M Return -26.77%
1Y Return -56.59%
Forward P/E N/M
Unified AI Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
1M Return +12.4%
1Y Return +31.01%
Forward P/E 14.8x
Unified AI Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GNPX -56.59% REGN +31.01% Spread: +87.6 pp (REGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GNPX TTM Op. Margin: 0.0% REGN TTM Op. Margin: 30.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs REGN. Trailing 12-month operating profitability (GNPX 0.0% vs REGN 30.4%) and valuation multiples (GNPX N/M vs REGN 14.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GNPX (0) vs REGN (10)
Institutional Metric GNPX REGN Criterion Row Winner
Market Capitalization Scale $2.2M $95.5B Larger Scale REGN
Trailing P/E Ratio Valuation N/M 20.4x Lower Multiple REGN
Forward P/E Ratio Valuation N/M 14.8x Lower Multiple REGN
Revenue Growth (YoY) Growth +0.0% +36.3% Higher Growth REGN
Operating Margin (TTM) Profitability 0.0% 30.4% Higher Margin REGN
Net Profit Margin Profitability 0.0% 28.5% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency -233.7% 14.9% Higher ROE REGN
52-Week Range Position Momentum 11% ($0โ€“$10) 82% ($592โ€“$992) Stronger Trend REGN
Beta / 30D Volatility Risk Regime -4.68ฮฒ ยท 96% Vol 0.30ฮฒ ยท 55% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 42.2 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GNPX vs REGN Buy Guide
GNPX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GNPX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GNPX nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.